Recce Pharmaceuticals Ltd (ASX: RCE) is making progress in its Phase II clinical trial for RECCE 327 Topical Gel (R327G), which targets Acute Bacterial Skin and Skin Structure Infections (ABSSSI). With 20 out of a planned 30 patients now dosed, all participants have experienced either complete recovery or substantial improvement, with no serious adverse effects reported—demonstrating R327G’s strong safety and effectiveness profile.
Dr. Alan W. Dunton, Chief Medical Advisor, noted that the favorable responses underscore R327G’s potential to tackle complex bacterial infections, including those related to diabetic foot ulcers. Expected to conclude in 2024, the study seeks to deliver an innovative topical treatment for ABSSSI, a market anticipated to reach USD 26 billion by 2032. Recce’s synthetic anti-infective line, which includes intravenous and oral therapies, addresses antibiotic resistance and has earned Fast Track designation and market exclusivity under the FDA’s GAIN Act.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
